Effects of Organic Anion Transporting Polypeptide (OATP1B1/SLCO1B1) Genetic Polymorphism on Statin Therapy
Ndubuisi N. NwobodoDepartment of Pharmacology and Therapeutics, Faculty of Clinical Medicinem, Ebonyi State University, Abakaliki, Nigeria.
Corresponding Author E-mail: nnwobodo@yahoo.com
Abstract: The 3-HMG-CoA reductase inhibitors (statins) which are substrates of OATP1B1 transporter protein, is reputed to be effective in reducing morbidity and mortality associated with cardiovascular disease. The OATP1B1 transporter protein is encoded by the SLCO1 genes and almost exclusively expressed in human liver cells. It plays a crucial role in the hepatic uptake and clearance of many drugs including statins. There is a high probability of drug-drug interactions since statins are co-administered with other drugs which may inhibit the OATP1B1 transporter leading to elevated serum levels and statin-induced adverse effects. The OATP1B1 (SLCO1B1) genetic polymorphism is quite invaluable in influencing clinical decisions on the use of statins. Consequently, genotyping for selected SLCO1B1 variants is recommended to identify individuals at increased risk of developing adverse drug effects following statin therapy.
Keywords: Clinical significance; Genetic polymorphism; OATP1B1; SLCO1B1; Statins Back to TOC